spacer

Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamivudine compared with continued treatment with dolutegravir/abacavir/lamivudine for virologically suppressed HIV infection (The AVERTAS trial): a randomised, open-label, superiority trial in Copenhagen, Denmark

Pedersen KBH, Knudsen A, Møller S, Siebner HR, Hove JD, Gerstoft J and Benfield T